Eyal C. Attar, SVP, Chief Medical Officer at Aprea Therapeutics, Inc. (APRE), bought 200 shares at $15.00 ($3K) on 2019-10-07, disclosed to the SEC on 2019-10-07.
Open-market purchase of $3k APRE by SVP, Chief Medical Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| VOR | SELL | 2024-12-31 | $13K | — | Filing → |
| VOR | SELL | 2024-06-04 | $20K | — | Filing → |
| APRE | SELL | 2022-03-01 | $62K | — | Filing → |